Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer.
الملخص
Objectives: Early detection of cancer comprises early diagnosis in symptomatic and screening of asymptomatic individuals. Our aim was to evaluate the significant values of carbohydrate antigen 15-3 (CA15-3) and/or Carcinoembryonic antigen (CEA) in women with breast cancer.
Design and setting: This case control study was conducted in Khartoum Teaching Hospital, Khartoum, Sudan.
Application of such measurement may be helpful within screening and early detection efforts in such a country like Sudan with poor resources.
Methods: We examined by serological radioimmuno-assay methods, significant elevation of CA15-3 and CEA serum samples obtained from 100 women of whom 40% and 35% were patients with histopathologically confirmed breast cancer and benign breast lumps respectively and the
remaining 25% were apparently healthy controls. Statistical analysis: Data were analyzed by using a computer SPSS program.
Results: Among the 75 patients with breast lumps, 33 (44%) and 31(37.3%) showed high CA15-3 and CEA levels respectively. Of the 40 carcinomas, high expressions of CA15-3 and CEA were found among 28(70%) and 24(60%) respectively. Notably, only 2(8%) of the controls showed lightly elevated CEA.
Conclusions: The obtained Specificity of 85.7%, 80% and sensitivity of 70%, 60% for CA15-3 and CEA correspondingly, support the combined application of both markers in screening for breast cancer.
المراجع
2. Gizira Isotope Centre for Molecular biology (GICMB), Sudan. Medical records, 2002.
3. Pons A, Krebs B, Mira R et al. Value of CA15-3 in the follow-up of breast cancer patients. Br J Cancer 1987;55:567-69.
4. Awadelkarim KD, Aceto G, Veschi S et al. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat 2007;102(2):189-99.
5. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989; 64:1674-1681.
6. Lauro S, Trasatti L, Bordin F et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999;19(4C):3511-5.
7. McLaughlin R, McGrath J, Grimes H et al. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cance. Int J Biol Markers 2000;15(4):340-2.
8. Shering S SF, Mcdermott E, O'higgins N et al. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83(12):2521-7.
9. Murray A WP, Price M, Dixon A et al. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer. Anticancer Res 1997;17:1945-50.
10. Duffy M. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52(3):345-51.
11. Jger W, Kr"Mer S, Palapelas V et al. Breast cancer and clinical utility of CA15-3 and CEA. Scand J Clin Lab Invest 1995;55(221):87-92.
12.American Society Of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
13.Bancroft J, Gamble M. Theory and practice of histological techniques. In. London: Churchill Livingstone; 2002;127.
14.Ruibal A, Colomer R, Genolla J. Pronostic value of CA15-3 serum level in patients having breast cancer. Horm Metab 1987;1:11-5.
15.Tampellini M, Berruti A, Gerbino A et al. Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997;75:698-702.
16.Krebs B, Pons A, Ramaioli A et al. Utilit? du CA15-3 dans le cancer du sein. Cancer commun 1988;2:55-64.
17.16.Molina R, Jo J, Filella X et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999;19(4A):2551-5.
18.Jessup J, Thomas P. Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev 1989;8:263-80.
19.Lucha PA Jr, Rosen L, Olenwine JA et al. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 1997;40:145-9.
20.Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D et al. Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004;67(5-6):359-67.
21.Omar Y, Behbehani A, Al Naqueeb N. Carcino-embryonic antigen and breast carcinoma antigen (CA 15-3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast. Int J Biol Markers 1988;3(3): 165-171.
22.Ai-Jarallah M, Behbehani A, El-Nass S. Serum CA 15-3 and CEA patterns in postsurgical follow-up and in monitoring clinical course of metastasis cancer in patients with, breast carcinoma. Eur J Surg Oncol 1993;19:174-79.
23.Naghshvar F, Torabizadeh Z, Emadian O et al. The diagnostic value of blood level of CEA and CA15-3 tumor markers in breast tumor with axillary lymph node metastases. Journal Of Mazandaran University Of Medical Sciences 2007;16(56):16-20.
24.Cooper E, De Mello Jj, Giles G. Biochemical markers in gastrointestinal malignancies. Arq Gastroenterol 1989;26(4):131-40.
25.Hayes D. Serum (circulating) tumor markers for breast cancer. In. Perry MC (ed) American Society of Clinical Oncology (ASCO) Educational Book Thirty-third Annual Meeting. 1997:228-233.
26.Canizares F, Sola J, Pérez M et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001;22(5):273-81.
27.Briasoulis E, Andreopoulou E, Tolis C et al. G-CSF induces elevation of circulating CA 15-3 inbreast carcinoma patients treated in an adjuvant setting. Cancer 2001;91(5):90 .١٧- ٩.
28.Kurebayashi J, Nomura T, Hirono M et al. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol 2006;36(3):150-3
